Key Takeaways
-
A nine-week course of immunotherapy before surgery left 100% of trial patients recurrence-free after nearly three years.
-
The treatment targets patients with a specific genetic profile present in 10 to 15% of stage two and three bowel cancer cases.
-
Personalized blood tests tracking tumor DNA proved highly effective at predicting how well patients responded to the treatment.
Groundbreaking trial offers new hope for bowel cancer patients
In a remarkable medical breakthrough, a clinical trial has demonstrated that a short course of immunotherapy before surgery can effectively “melt away” bowel cancer and keep it from returning. Following a pioneering study, researchers found that patients with a specific genetic form of stage two or three bowel cancer remained completely cancer-free nearly three years after receiving the treatment.
During the NEOPRISM-CRC trial, 32 patients were given the immunotherapy drug pembrolizumab for up to nine weeks prior to their planned surgeries. This approach replaced the traditional standard of care, which typically involves surgery followed by months of chemotherapy. Remarkably, after 33 months of rigorous follow-up, zero patients experienced a cancer recurrence. By contrast, the standard treatment usually sees a relapse rate of around 25% within three years.
One participant, 73-year-old Christopher Burston, was diagnosed with stage 3 bowel cancer following a routine screening. After receiving three doses of immunotherapy over nine weeks, his doctors found that the substantial tumor had essentially vanished. More than three years later, Christopher remains cancer-free and has happily returned to his normal life.
In addition to the extraordinary survival outcomes, scientists successfully utilized personalized blood tests to track tumor DNA in the bloodstream. These tests provided critical early indicators of whether the treatment was working, allowing medical professionals to accurately predict patient responses. Experts hope this innovative combination of highly targeted immunotherapy and personalized monitoring could soon transform how we approach and conquer high-risk bowel cancers.
